1249. Deputy Ken O'Flynn asked the Minister for Health whether any internal audit reports, governance reviews, expenditure-control assessments, or value-for-money evaluations relating to the treatment abroad scheme have been conducted by the HSE, Department of Health, Internal Audit, National Financial Regulations Office, or any external body since 2020; and if she will provide details of same. [39142/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn under the heading Departmental Schemes.
146 questions match, newest first.
1250. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme appears on any HSE or Departmental corporate risk register, strategic risk register, or internal assurance framework; and if so, the risks identified. [39143/26]
1251. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme operates any formal benchmarking process comparing the cost of equivalent procedures across jurisdictions prior to authorisation approval. [39144/26]
1253. Deputy Ken O'Flynn asked the Minister for Health whether any fraud-prevention, duplicate-payment detection, or abnormal expenditure-monitoring system is operated in respect of the treatment abroad scheme. [39146/26]
1254. Deputy Ken O'Flynn asked the Minister for Health whether any internal threshold, trigger mechanism or anomaly detection system exists within the treatment abroad scheme to identify unusually high-cost invoices received from healthcare providers in other EU/EEA states. [39149/26]
1255. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has ever formally disputed, queried, challenged or sought clarification regarding the cost of treatment invoiced under the treatment abroad scheme by another EU/EEA healthcare system; and if she will provide the number of such cases since 2020. [39150/26]
1256. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any comparative database or benchmarking framework examining the average cost of equivalent procedures between different EU/EEA healthcare systems under the treatment abroad scheme. [39151/26]
1257. Deputy Ken O'Flynn asked the Minister for Health whether any value-for-money analysis has been conducted comparing expenditure under the treatment abroad scheme against the cost of developing equivalent treatment capacity domestically. [39153/26]
1258. Deputy Ken O'Flynn asked the Minister for Health whether any internal financial escalation process exists within the HSE or Department of Health for treatment abroad scheme cases exceeding specified expenditure levels; and if she will provide details of the approval pathway applying in such cases. [39154/26]
1259. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme operates under any internal delegated financial authority limits; and if she will provide the approval thresholds applying at local, national and departmental level. [39155/26]
1260. Deputy Ken O'Flynn asked the Minister for Health the number of treatment abroad scheme cases since 2020 where the total expenditure exceeded €100,000, €250,000, €500,000 and €1 million respectively. [39156/26]
1261. Deputy Ken O'Flynn asked the Minister for Health whether her Health receives routine reporting regarding exceptionally high-cost treatment abroad scheme cases; and if so, the format and frequency of such reporting. [39157/26]
1262. Deputy Ken O'Flynn asked the Minister for Health whether any value-for-money assessment, benchmarking exercise or cost comparison is undertaken before approval of high-cost treatment abroad scheme referrals. [39158/26]
1263. Deputy Ken O'Flynn asked the Minister for Health whether any internal risk assessment has been carried out regarding financial exposure under the treatment abroad scheme arising from the absence of expenditure thresholds or cost ceilings. [39159/26]
1265. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains formal written financial approval thresholds for expenditure under the treatment abroad scheme; and if she will provide the monetary values applicable at each approval level. [39161/26]
1266. Deputy Ken O'Flynn asked the Minister for Health whether any treatment abroad scheme applications since 2020 required escalation beyond the Treatment Abroad Office in Kilkenny for approval; and if she will provide the number of such cases by year. [39162/26]
1267. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains a formal escalation framework for exceptionally high-cost, novel, clinically complex or non-routine treatment abroad scheme referrals. [39163/26]
1268. Deputy Ken O'Flynn asked the Minister for Health whether any treatment abroad scheme approvals since 2020 required review or sign-off by senior HSE management above Grade VIII level; and if she will provide details by year and grade level involved. [39164/26]
1269. Deputy Ken O'Flynn asked the Minister for Health whether the Department of Health receives routine reporting relating to high-cost treatment abroad scheme approvals, aggregate expenditure trends or exceptional financial exposures arising under the scheme. [39165/26]
1270. Deputy Ken O'Flynn asked the Minister for Health whether any Ministerial approval, notification or Departmental sanction process exists for treatment abroad scheme cases exceeding specified expenditure thresholds. [39166/26]
1271. Deputy Ken O'Flynn asked the Minister for Health the highest individual expenditure amount approved under the treatment abroad scheme in each year since 2020. [39167/26]
1272. Deputy Ken O'Flynn asked the Minister for Health whether internal audit has examined the governance, approval controls or financial oversight arrangements of the treatment abroad scheme since 2020; and if she will provide the dates and titles of any such audits. [39168/26]
1273. Deputy Ken O'Flynn asked the Minister for Health whether any external value-for-money review, governance review or expenditure-control assessment of the treatment abroad scheme has been conducted since 2020. [39169/26]
1274. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has identified any governance, financial-control or accountability risks arising from the absence of publicly available approval thresholds within the treatment abroad scheme. [39170/26]
1275. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains written procedures governing approval authority for treatment abroad scheme applications by staff grade or management level. [39171/26]